The administration of l-thyroxine as soft gel capsule or liquid solution

Expert Opinion on Drug Delivery

Volumn 11, Issue 7, 2014, Pages 1103-1111

  Vita, Roberto ^a   Fallahi, Poupak ^b   Antonelli, Alessandro ^b   Benvenga, Salvatore ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Drugs; Intestinal absorption; Levothyroxine; Oral solution; Soft gel capsule

Indexed keywords

BAGOTHYROX; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; THYROTROPIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BARIATRIC SURGERY; COFFEE; CONGENITAL HYPOTHYROIDISM; DISEASE SEVERITY; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MARKETING; DRUG SOLUBILITY; DRUG STRUCTURE; FOLLOW UP; HUMAN; HYPOTHYROIDISM; IN VITRO STUDY; INTESTINE ABSORPTION; LIQUID; MALABSORPTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PH; PHARMACOKINETICS; PHYSICIAN; PRESCRIPTION; REVIEW; SOFT GEL CAPSULE; SUBSTITUTION THERAPY; SWALLOWING; TABLET; THYROTROPIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

DRUGS; INTESTINAL ABSORPTION; LEVOTHYROXINE; ORAL SOLUTION; SOFT GEL CAPSULE;

ADMINISTRATION, ORAL; ANIMALS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; GELS; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL SOLUTIONS; TABLETS; THYROXINE;

EID: 84903188442     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.918101     Document Type: Review

References (60)

1. Garber JR, Cobin RH, Gharib H, et al. American Association of Clinical Endocrinologists and American Thyroid Association Task Force on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: Co-sponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012;18(6):988-1028
2. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev 2014. [Epub ahead of print]
3. The authors address thoroughly the main issues concerning the treatment with L-T4
4. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
5. Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am 2012;96:369-83
6. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008;62:559-63
7. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012;97:1134-45
8. Kendall EC. Landmark article, June 19, 1915 The isolation in crystalline form of the compound containing iodine, which occurs in the thyroid Its chemical nature and physiologic activity. JAMA 1983;250:2045-6
9. Lindholm J, Laurberg P. Hypothyroidism and thyroid substitution: Historical aspects. J Thyroid Res 2011;2011:809341
10. Braverman LE, Ingbar SH, Sterling K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J Clin Invest 1970;49:855-64
11. Bunevicius R, Kazanavicius G, Zalinkevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999;340:424-9 (Pubitemid 29084773
12. Appelhof BC, Fliers E, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: A double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005;90:2666-74 (Pubitemid 40686307
13. Clyde PW, Harari AE, Getka EJ, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: A randomized controlled trial. JAMA 2003;290:2952-8 (Pubitemid 37505527
14. Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, et al. Thyroid hormone replacement therapy in primary hypothyroidism: A randomized trial comparing L-Thyroxine plus liothyronine with L-Thyroxine alone. Ann Intern Med 2005;142:412-24
15. Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA Guidelines: The use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012;1:55-71
16. Biondi B, Wartofsky L. Combination treatment with T4 and T3: Toward personalized replacement therapy in hypothyroidism?. J Clin Endocrinol Metab 2012;97:2256-71
17. Eadala P, Waud JP, Matthews SB, et al. Quantifying the 'hidden' lactose in Drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther 2009;29:677-87
18. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787-95
19. Hays MT, Nielsen RK. Human thyroxine absorption: Age effects and methodological analyses. Thyroid 1994;4:55-64 (Pubitemid 24145888
20. Benvenga S, Bartolone L, Squadrito S, et al. Delayed intestinal absorption of levothyroxine. Thyroid 1995;5:249-53
21. Hays MT. Localization of human thyroxine absorption. Thyroid 1991;1:241-8
22. Walter-Sack I, Clanget C, Ding R, et al. Assessment of levothyroxine sodium bioavailability. Clin Pharmacokinet 2004;43:1037-53
23. Bach-Huynh TG, Nayak B, Loh J, et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009;94:3905-12
24. Virili C, Bassotti G, Santaguida MG, et al. Atypical celiac disease as cause of increased need for thyroxine: A systematic study. J Clin Endocrinol Metab 2012;97:E419-22
25. Asik M, Gunes F, Binnetoglu E, et al. Decrease in TSH levels after lactose restriction in Hashimoto's thyroiditis patients with lactose intolerance. Endocrine 2013. [Epub ahead of print]
26. Liwampo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 2009;23:781-92
27. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010;11:41-50
28. Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol 2005;60:337-41 (Pubitemid 41224144
29. Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of coffee caused by coffee. Thyroid 2008;18:293-301 (Pubitemid 351415797
30. Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007;13:345-9
31. Benvenga S, Ruggeri RM, Trimarchi F. Thyroid and drugs In: Monaco F, editors. Thyroid Diseases. CRC Press; Boca Raton, FL: 2012. p. 482-3
32. Patanè S, Marte F. Acute myocardial infarction During L-Thyroxine therapy in a patient with intermittent changing axis deviation, permanent atrial fibrillation and without significant coronary stenoses Int J Cardiol 2010;138:e8-11
33. Peterson RE. The influence of the thyroid on adrenal cortical function. J Clin Invest 1958;37:736-43
34. Raghavan S, DiMartino-Nardi J, Saenger P, et al. Pseudotumor cerebri in an infant after L-Thyroxine therapy for transient neonatal hypothyroidism. J Pediatr 1997;130:478-80 (Pubitemid 27492698
35. Nourbakhsh A, Ahmed HA, McAuliffe TB, et al. Case report: Bilateral slipped capital femoral epiphyses and hormone replacement. Clin Orthop Relat Res 2008;466:743-8 (Pubitemid 351903843
36. Tsutaoka BT, Kim S, Santucci S. Seizure in a child after an acute ingestion of levothyroxine. Pediatr Emerg Care 2005;21:857-9 (Pubitemid 41813020
37. A booklet for patients and their families. A publication of the American Thyroid Association (ATA). 2013. Available from: Http://www.thyroid.org/wp- content/ uploads/patients/brochures/ hypothyroidism-web-booklet.pdf [Last Accessed 9 February 2014]
38. T€onjes A, Karger S, Koch CA, et al Impaired enteral levothyroxine absorption in hypothyroidism refractory to oral therapy after thyroid ablation for papillary thyroid cancer: Case report and kinetic studies. Thyroid 2006;16:1047-51 (Pubitemid 46141308
39. Anderson L, Joseph F, Goenka N, et al Isolated thyroxine malabsorption treated with intramuscular thyroxine injections. Am J Med Sci 2009;337:150-2
40. Torres MS, Emerson CH. Myxedema coma In: Irwin RS, Rippe JM, editors Irwin & Rippe's intensive care medicine. 7th edition. Lippincott Williams and Wilkins, Philadelphia, PA; 2011. p. 1055-8
41. Colucci P, D'Angelo P, Mautone G, et al. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther Drug Monit 2011;33:355-61
42. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm 2009;72:105-10
43. Benvenga S, Ducharme MP. Effect of proton pump inhibitors (PPIs) on the relative bioavailability of levothyroxine (L-T4) in soft gel capsules and in tablets. Program and Abstract book of the 82nd Annual Meeting of the American Thyroid Association; 19-23 September 2012; Quebec City, Canada. Thyroid 2012;22(S1):A50
44. Vita R, Benvenga S. Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor: A problem that was solved by switching to L-T4 in soft gel capsule. Endocr Pract 2014;Mar;1;20(3):e38-41
45. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-Thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 2013;43:154-60
46. De Grazia S, Carlomagno G, Unfer V, et al. Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. Expert Opin Drug Deliv 2012;9:1033-9
47. Santaguida M, Virili C, Gatto I, et al. A novel therapeutic approach for patients with gastric disorders and T4 malabsorption: Thyroxine softgel preparation. Thyroid 2013;23(S1):A53
48. Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr 2013;162:1264-9
49. O'Leary CM, Nassar N, Zubrick SR, et al. Evidence of a complex association between Dose, pattern and timing of prenatal alcohol exposure and child behaviour problems. Addiction 2010;105:74-86
50. Bernareggi A, Grata E, Pinorini MT, et al. Oral liquid formulation of Levothyroxine is stable in breakfast and may improve thyroid patient compliance. Pharmaceutics 2013;5:621-33
51. Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 2012;62:631-6
52. Cappelli C, Pirola I, Gandossi E, et al. Oral liquid levothyroxine treatment at breakfast: A mistake?. Eur J Endocrinol 2013;170:95-9
53. Le Traon G, Burgaud S, Horspool LJ. Pharmacokinetics of total thyroxine in Dogs after administration of an oral solution of levothyroxine sodium. J Vet Pharmacol Therap 2008;31:95-101 (Pubitemid 351326742
54. Peroni E, Vigone MC, Mora S, et al. Congenital hypothyroidism treatment in infants: A comparative study between liquid and tablet formulations of levothyroxine. Horm Res Paediatr 2014;81:50-4
55. Brancato D, Scorsone A, Saura G, et al. Comparison of TSH levels with liquid formulation versus tablet formulations of levothyroxine in the treatment of adult hypothyroidism. Endocr Pract 2014. [Epub ahead of print]
56. Vita R, Saraceno G, Trimarchi F, et al. A novel formulation of levothyroxine (oral solution) is resistant to the levothyroxine malabsorption induced by proton-pump inhibitors (PPI). Thyroid 2013;23(S1):A-71
57. Pirola I, Formenti AM, Gandossi E, et al. Oral liquid L-Thyroxine (L-T4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes Surg 2013;23:1493-6
58. Benvenga S. When thyroid hormone replacement is ineffective?. Curr Opin Endocrinol Diabetes Obes 2013;20:467-58
59. Boelaert K. Thyroid dysfunction in the elderly. Nat Rev Endocrinol 2013;9:194-204
60. Le Couteur DG, Hilmer SN, Glasgow N, et al. Prescribing in older people. Aust Fam Physician 2004;33:777-81